Erik Leonardo Mateos Salgado, Fructuoso Ayala Guerrero, Beatriz Eugenia Del Olmo Alcántara
{"title":"Evaluación de la fragmentación del sueño en niños con trastorno del espectro autista","authors":"Erik Leonardo Mateos Salgado, Fructuoso Ayala Guerrero, Beatriz Eugenia Del Olmo Alcántara","doi":"10.1016/j.psiq.2023.100428","DOIUrl":"https://doi.org/10.1016/j.psiq.2023.100428","url":null,"abstract":"<div><h3>Introduction</h3><p>Disruption in sleep continuity can be assessed by the sleep fragmentation index (SFI), a measure that has proven useful in the evaluation of individuals with various sleep disorders. Problems with sleep structure are present in autism spectrum disorder (ASD), but the SFI has not been evaluated in this type of population. The aim of this study was to evaluate the characteristics of the SFI in a group of children with ASD and in a group of typically developing (TD) children.</p></div><div><h3>Methods</h3><p>Polysomnography recordings were performed in 19 children with ASD of mean age 10.1 (± 2.5) years and in 19 children with TD of mean age 10.8 (± 2.5) years. In both groups, the Mann Whitney U test was used to compare the SFI , total sleep time, percentages of sleep stages, wake after sleep onset, sleep onset latency and REM sleep latency.</p></div><div><h3>Results</h3><p>Of the sleep variables evaluated, in the ASD group the percentage of REM sleep was significantly lower, while REM sleep latency was significantly higher.</p></div><div><h3>Conclusions</h3><p>Sleep fragmentation is not a characteristic feature of ASD. Significant variation in REM sleep provides evidence in favor of the hypothesis of REM sleep deficiency in ASD.</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 3","pages":"Article 100428"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134656702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Schizophrenia is associated with severe consequences","authors":"Kalyani Rajalingham","doi":"10.1016/j.psiq.2023.100413","DOIUrl":"https://doi.org/10.1016/j.psiq.2023.100413","url":null,"abstract":"<div><p><span>Schizophrenia is an illness that affects millions of individuals. It is typically accompanied by positive, negative and cognitive symptoms. These symptoms are typically associated with the onset and progression of schizophrenia. However, aside from these known symptoms, there are consequences of having schizophrenia. In particular, metabolic syndrome<span>, early death and suicide, diseases<span>, lowered pain perception, sexual dysfunction, aggressive behavior/victimization, stigma, and </span></span></span>cognitive deficit<span> are all consequences of having schizophrenia. In this paper, we review the various consequences of having schizophrenia. These consequences should be monitored for, much like the typical symptoms, but are usually omitted from treatment.</span></p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 2","pages":"Article 100413"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49878507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pablo Vázquez-Herrera , Sara Cabezas-Gutierrez , Batirtze Goitia-Aritxa
{"title":"La catatonia. Diagnóstico y tratamiento a propósito de un caso","authors":"Pablo Vázquez-Herrera , Sara Cabezas-Gutierrez , Batirtze Goitia-Aritxa","doi":"10.1016/j.psiq.2023.100396","DOIUrl":"https://doi.org/10.1016/j.psiq.2023.100396","url":null,"abstract":"<div><p>The catatonic syndrome present multiple etiologies, both medical and psychiatric, with a variety of symptoms that often escape the clinical eye; therefore, it is currently an underdiagnosed syndrome. A multidisciplinary and global approach is necessary in these patients, due to the wide range of pharmacological, toxic and organic predisposing factors and the high morbidity and mortality of this syndrome. That is why we show a clinical case of an inhibited catatonic syndrome in a 37-year-old patient diagnosed with hebephrenic schizophrenia who presents a clinical picture of stupor, mutism and negativism.</p><p>In-depth training for clinicians and the application of up-to-date diagnostic scales and criteria are of vital importance for diagnosis, evolution and treatment of these patients. The use of benzodiazepines and early electroconvulsive therapy are the first-line treatments, always associated with support measures and prevention of complications.</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 2","pages":"Article 100396"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49857053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luz María González Gualda , Rocío Sáez Povedano , Paloma Cano-Ruiz , Miguel Barberán Navalón
{"title":"Tiaprida, una alternativa de tratamiento en el trastorno por uso de alcohol: a propósito de un caso","authors":"Luz María González Gualda , Rocío Sáez Povedano , Paloma Cano-Ruiz , Miguel Barberán Navalón","doi":"10.1016/j.psiq.2023.100393","DOIUrl":"https://doi.org/10.1016/j.psiq.2023.100393","url":null,"abstract":"<div><h3>Objective</h3><p>Present a clinical case report on the use of tiapride for alcohol detoxification in a patient with a diagnosis of severe alcohol use disorder 303.90 (F10.20).</p></div><div><h3>Clinical case report</h3><p>50 year-old female, under follow-up in the Addictive Behavior Unit from September 2016 to present, with diagnoses of adjustment disorder 309.4 (F43.25)</p><p>Mixed disturbance of emotions or behavior, severe alcohol use disorder 303.90 (F10.20) and severe decompensation, who is treated with tiapride.</p></div><div><h3>Results</h3><p>The studies consulted demonstrate the efficacy and safety of tiapride for alcohol withdrawal syndrome in both outpatient and inpatient settings, in monotherapy or in polytherapy with benzodiazepines and/or antiepileptics, being also used in agitation and/or psychotic symptomatology.</p></div><div><h3>Conclusions</h3><p>In alcohol withdrawal syndrome, tiapride has been found to be effective and can even be considered as an adjunctive treatment to benzodiazepines or anticonvulsants. With a view to the future, pharmacogenetics affecting alcohol use disorder should be taken into account, so that individualized personalized therapy could benefit from fewer adverse effects.</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 2","pages":"Article 100393"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49841731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Respiratory depression caused by low dose of olanzapine: A case report","authors":"Masatoshi Inoue","doi":"10.1016/j.psiq.2023.100412","DOIUrl":"https://doi.org/10.1016/j.psiq.2023.100412","url":null,"abstract":"<div><h3>Objective</h3><p><span>Olanzapine is widely used throughout the world to treat patients with schizophrenia and </span>bipolar disorder<span>. Olanzapine has numerous side effects, but respiratory depression has not been reported with doses as low as 5 mg.</span></p></div><div><h3>Clinical case</h3><p>An elderly woman presented with severe hypercarbia<span>, hypoxia<span>, and impaired consciousness possibly due to low doses of oral olanzapine. There is no accepted antidote for the side effects of olanzapine, so we followed the patient with respiratory support and electrolyte correction. Symptoms improved after 2 weeks and did not recur.</span></span></p></div><div><h3>Results and conclusions</h3><p>Elderly patients, women, and non-smokers may have elevated olanzapine concentrations and may do better with lower than usual doses. If somnolence<span> is observed in a patient taking olanzapine, a blood gas should be obtained and appropriate respiratory care should be provided. We expect that this case report will add to the existing body of literature on the appropriate use of olanzapine.</span></p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 2","pages":"Article 100412"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49878508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
María-José Alvarez , Ricardo López-Escribano , Ana Marzán , Luis Alonso-Alvarez
{"title":"Delayed-onset posttraumatic stress disorder with response to methylphenidate","authors":"María-José Alvarez , Ricardo López-Escribano , Ana Marzán , Luis Alonso-Alvarez","doi":"10.1016/j.psiq.2023.100397","DOIUrl":"https://doi.org/10.1016/j.psiq.2023.100397","url":null,"abstract":"<div><h3>Introduction</h3><p>Posttraumatic stress disorder<span> (PTSD) is extremely frequent in war veterans and has been widely studied. However, the efficacy of currently available pharmacological and psychotherapeutic treatments of war PTSD and other causes of PTSD is very limited.</span></p></div><div><h3>Method</h3><p>We present a case of war PTSD with delayed expression, with a good response to complementation with methylphenidate<span> after a failed treatment with venlafaxine<span> and risperidone.</span></span></p></div><div><h3>Results</h3><p><span><span><span>We review the role of dopamine in the pathophysiology of PTSD and the scarce studies in the treatment of PTSD with </span>dopaminergic </span>drugs<span> that show an improvement in re-experimentation and in affective symptoms, especially anhedonia and </span></span>cognitive impairment.</p></div><div><h3>Conclusions</h3><p>We conclude that the use of methylphenidate and other dopaminergic drugs can be a promising treatment for PTSD, a high prevalent disease with a high resistance to treatment, for which we encourage the use of large sample studies.</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 2","pages":"Article 100397"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49841733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Olanzapina, 26 años: situación actual, conocimientos, actitudes y prácticas de uso entre los psiquiatras españoles","authors":"Jairo M. Gonzalez-Diaz , Miquel Bernardo","doi":"10.1016/j.psiq.2022.100391","DOIUrl":"https://doi.org/10.1016/j.psiq.2022.100391","url":null,"abstract":"<div><p>Olanzapine, a second-generation antipsychotic marketed in Europe since late 1996, continues to be one of the most widely used molecules in Spain today. However, its high rate of adverse metabolic events and its use in some clinical settings are still controversial. The objective of this study was to explore the knowledge, attitudes, and practices of use of this medication among Spanish psychiatrists. A self-filled questionnaire was designed and distributed. Dosage, experience, and trends of use in different contexts were explored, as well as future expectations. Data were tabulated and a descriptive analysis was performed. 129 practicing psychiatrists throughout the Spanish territory participated in the study, with an average age of 45.46 years (SD<!--> <!-->=<!--> <!-->9.57) and a female: male ratio of 1.04:1. After more than 25 years on the market, Olanzapine continues to be an antipsychotic widely used in different clinical settings, both in Schizophrenia and other mental disorders (preferably at doses between 5 and 10 mg/day). Spanish psychiatrists are familiar with the need to establish pharmacological and non-pharmacological strategies for the metabolic control of patients using this drug.</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 1","pages":"Article 100391"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49868833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Josep Deví-Bastida , Helena Puig-Martel , Santiago Llana-Cortés , Alexandra García-Guix , M. Teresa Abellán-Vidal , M. Dolores López-Villegas
{"title":"Relación entre la cantidad y el tipo de alcohol (destilado versus fermentado) consumido y el riesgo de aparición de deterioro cognitivo compatible con un síndrome demencial en personas mayores de 60 años: revisión sistemática","authors":"Josep Deví-Bastida , Helena Puig-Martel , Santiago Llana-Cortés , Alexandra García-Guix , M. Teresa Abellán-Vidal , M. Dolores López-Villegas","doi":"10.1016/j.psiq.2023.100395","DOIUrl":"https://doi.org/10.1016/j.psiq.2023.100395","url":null,"abstract":"<div><h3>Introduction</h3><p>Alcohol is the most consumed substance in Western culture and its consumption is a causal factor in more than 200 diseases and disorders. The objective was to determine the relationship between the amount and type of alcohol (distilled or fermented) consumed, in individuals over 60 years of age, and the appearance of cognitive deterioration compatible with a dementia syndrome as a consequence of excessive and prolonged consumption.</p></div><div><h3>Development</h3><p>Search in Medline, PsycInfo and Web of Science databases. The search was limited to articles published between 2010 and 2021, based on the combination of various terms related to dementia, alcohol consumption and type, and old age. 157 articles were obtained, those repeated and those not related to the topic were eliminated, leaving a total of 9 articles. This systematic review has been carried out in accordance with the criteria of the PRISMA statement.</p></div><div><h3>Conclusions</h3><p>Most of the studies found (7 out of 9) suggested an association between alcohol consumption and the onset of dementia. Regarding the type of beverages, everything and the objectification of some inconclusive results, in general it is suggested that the consumption of wine (fermented beverage) is associated with a decrease of cognitive deterioration and the consumption of liquor (distilled beverage) to a increased cognitive decline; the role of beer is not clear. Therefore, it can be concluded that the association between alcohol consumption and greater or lesser cognitive impairment depends both on excessive and prolonged consumption, as well as on the type of beverages consumed (distilled or fermented).</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":"30 1","pages":"Article 100395"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49868832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}